ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 154 filers reported holding ENANTA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $315,500 | +15.5% | 14,743 | +118.4% | 0.04% | +8.6% |
| Q1 2023 | $273,051 | +14.3% | 6,752 | +31.4% | 0.04% | +12.9% |
| Q4 2022 | $238,973 | +15.4% | 5,137 | +28.9% | 0.03% | +6.9% |
| Q3 2022 | $207,000 | -2.8% | 3,986 | -11.3% | 0.03% | +3.6% |
| Q2 2022 | $213,000 | -8.2% | 4,496 | +37.7% | 0.03% | +3.7% |
| Q1 2022 | $232,000 | -9.0% | 3,266 | -4.2% | 0.03% | -6.9% |
| Q4 2021 | $255,000 | +8.1% | 3,408 | -18.0% | 0.03% | -3.3% |
| Q3 2021 | $236,000 | +15.1% | 4,158 | -0.0% | 0.03% | -3.2% |
| Q1 2021 | $205,000 | -7.7% | 4,160 | -21.1% | 0.03% | -36.7% |
| Q4 2020 | $222,000 | -6.3% | 5,270 | +11.8% | 0.05% | -40.2% |
| Q2 2020 | $237,000 | 0.0% | 4,712 | +2.2% | 0.08% | -13.7% |
| Q1 2020 | $237,000 | – | 4,609 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 511,186 | $43,686,000 | 11.23% |
| GREAT POINT PARTNERS LLC | 210,400 | $17,981,000 | 2.80% |
| ARMISTICE CAPITAL, LLC | 456,000 | $38,970,000 | 2.34% |
| Matarin Capital Management, LLC | 210,208 | $17,964,376,000 | 1.16% |
| Sapphire Star Partners LP | 8,168 | $698,000 | 0.70% |
| Granahan Investment Management | 103,320 | $8,830,000 | 0.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 867,500 | $74,137,000 | 0.44% |
| 361 CAPITAL LLC | 19,040 | $1,627,000 | 0.35% |
| ALGERT GLOBAL LLC | 17,922 | $1,532,000 | 0.33% |
| AlphaMark Advisors, LLC | 9,310 | $796,000 | 0.32% |